Physician profile
Chris D Cheyne
NPI 1831192962
$6,131.26
in general payments reported to CMS, 2019-2025
24 companies · $818 in 2025
The $818 reported for 2025 was more than what 88% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,000 · 2020: $385 · 2021: $718 · 2022: $737 · 2023: $758 · 2024: $1,715 · 2025: $818.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,291.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,291.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,052.43 | 2019-2025 | Total30, Dailies Total1, Precision 1 |
| Bausch & Lomb Americas INC. | $1,002.48 | 2022-2025 | Infuse, Btod, Biotrue One Day |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $908.94 | 2019-2021 | |
| Lumenis Be INC | $734.83 | 2024 | Optilight |
| Coopervision INC. | $594.48 | 2019-2025 | Myday Contact Lens, Clariti Contact Lens |
| Optos, INC. | $286.02 | 2019-2022 | |
| Glaukos Corporation | $248.17 | 2020-2024 | Radius |
| Oculus, INC. | $235.09 | 2019 | |
| Lkc Technologies, INC. | $232.14 | 2023-2025 | |
| Johnson & Johnson Vision Care, INC. | $124.24 | 2019 | |
| Genzyme Corporation | $99.98 | 2019 | |
| Abbvie INC. | $90.25 | 2022-2023 | Lumigan, Vuity |
| Biotissue Holdings INC. | $82.82 | 2024-2025 | |
| Tarsus Pharmaceuticals, INC. | $80.44 | 2024-2025 | Xdemvy |
| Sun Pharmaceutical Industries INC. | $72.62 | 2021-2024 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abb Con-Cise Optical Group LLC | $69.03 | 2025 | Contact Lens |
| Lombart Brothers, INC. | $57.42 | 2023-2024 | Opd-III |
| Kala Pharmaceuticals, INC. | $41.71 | 2021 | |
| Carl Zeiss Meditec USA, INC. | $24.35 | 2023 | Cirrus Hd-Oct |
| Sight Sciences, INC. | $23.62 | 2020 | |
| Allergan, INC. | $21.41 | 2022 | |
| Novartis Pharmaceuticals Corporation | $18.43 | 2022 | |
| Oyster Point Pharma, INC. | $17.77 | 2023 | Tyrvaya |
| Maculogix, INC. | $12.59 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chris Cheyne listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.